Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function

Cited by (565)

Items 101–200 of 565

1. Mechanisms of T cell exhaustion guiding next-generation immunotherapy
   Zebley, Caitlin C., Youngblood, Ben · 2022 · Trends in Cancer
2. Genome-wide CRISPR-Cas9 screening in mammalian cells
   Jason Yu, Kosuke Yusa · 2019 · Methods
3. A T cell resilience model associated with response to immunotherapy in multiple tumor types
   Yu Zhang, Trang Vu, Douglas C. Palmer, Rigel J. Kishton, Lanqi Gong, Jiao Huang, Thanh Nguyen, Zuojia Chen, Cari Smith, Ferenc Livák et al. · 2022 · Nature Medicine
4. Type 1 regulatory T cell-mediated tolerance in health and disease
   Robert Arthur Freeborn, Steven Strubbe, Maria Grazia Roncarolo · 2022 · Frontiers in Immunology
5. Systematic reconstruction of molecular pathway signatures using scalable single-cell perturbation screens
   Longda Jiang, Carol Dalgarno, Efthymia Papalexi, Isabella Mascio, Hans‐Hermann Wessels, Huiyoung Yun, Nika Iremadze, Gila Lithwick‐Yanai, Doron Lipson, Rahul Satija · 2025 · Nature Cell Biology
6. Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity
   Shijun Ma, Li-Teng Ong, Zemin Jiang, Wee Chyan Lee, Puay Leng Lee, Mubaraka Yusuf, Henrik J. Ditzel, Yulan Wang, Qingfeng Chen, Wenyu Wang et al. · 2024 · Cancer Cell
7. Systematic discovery of CRISPR-boosted CAR T cell immunotherapies
   Paul Datlinger, Eugenia V. Pankevich, Cosmas D. Arnold, Nicole Pranckevicius, Jenny Lin, Daria Romanovskaia, Moritz Schaefer, Francesco Piras, Anne-Christine Orts, Amelie Nemc et al. · 2025 · Nature
8. Systems immunology: Integrating multi-omics data to infer regulatory networks and hidden drivers of immunity
   Jiyang Yu, Junmin Peng, Hongbo Chi · 2019 · Current Opinion in Systems Biology
9. Layilin augments integrin activation to promote antitumor immunity
   Kelly M. Mahuron, Joshua Michael Moreau, Jeff E. Glasgow, Devi P Boda, Mariela L. Pauli, Victoire Gouirand, Luv Panjabi, Robby Grewal, Jacob M. Luber, Anubhav N. Mathur et al. · 2020 · The Journal of Experimental Medicine
10. Delivery Approaches for Therapeutic Genome Editing and Challenges
    Ilayda Ates, Tanner Rathbone, Callie Stuart, P. Hudson Bridges, Renee N. Cottle · 2020 · Genes
11. Engineering chimeric antigen receptor T cells for solid tumour therapy
    Longwei Liu, Yunjia Qu, Leonardo Cheng, Chi Woo Yoon, Peixiang He, Abdula Monther, Tianze Guo, Sarah J. Chittle, Yingxiao Wang · 2022 · Clinical and Translational Medicine
12. Future perspectives on engineered T cells for cancer
    Avery D. Posey, Regina M. Young, Carl H. June · 2024 · Trends in cancer
13. Engineered natural killer cells for cancer therapy
    Alexander Biederstädt, Katayoun Rezvani · 2025 · Cancer Cell
14. gscreend: modelling asymmetric count ratios in CRISPR screens to decrease experiment size and improve phenotype detection
    Katharina Imkeller, Giulia Ambrosi, Michael Boutros, Wolfgang K. Huber · 2020 · Genome biology
15. Loss of Rnf31 and Vps4b sensitizes pancreatic cancer to T cell-mediated killing
    Nina Frey, Luigi Tortola, David Egli, Sharan Janjuha, Tanja Rothgangl, Kim Fabiano Marquart, Franziska Ampenberger, Manfred Köpf, Gerald Schwank · 2022 · Nature Communications
16. SOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity
    Grace M. Bidgood, Narelle Keating, Karen Doggett, Sandra E. Nicholson · 2024 · Frontiers in Immunology
17. CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More
    Xuejin Ou, Qizhi Ma, Wei Yin, Xuelei Ma, Zhiyao He · 2021 · Frontiers in Cell and Developmental Biology
18. Genome-wide fitness gene identification reveals Roquin as a potent suppressor of CD8 T cell expansion and anti-tumor immunity
    Hanfei Zhao, Ying Liu, Lixia Wang, Gang Jin, Xiaocui Zhao, Jing Xu, Guangyue Zhang, Yuying Ma, Na Yin, Min Peng · 2021 · Cell Reports
19. CRISPR–Cas9 applications in T cells and adoptive T cell therapies
    Xiaoying Chen, Shuhan Zhong, Yonghao Zhan, Xuepei Zhang · 2024 · Cellular & Molecular Biology Letters
20. CRISPR-Based Tools in Immunity
    Dimitre R. Simeonov, Alexander Marson · 2019 · Annual Review of Immunology
21. Pooled Screens Identify GPR108 and TM9SF2 as Host Cell Factors Critical for AAV Transduction
    Walter Hans Meisen, Zahra Bahrami-Nejad, Miki Hardy, Huiren Zhao, Oliver Oliverio, Songli Wang, Christopher M. Hale, Michael M. Ollmann, Patrick J. Collins · 2020 · Molecular Therapy — Methods & Clinical Development
22. Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency
    Alexander Biederstädt, Rafet Başar, Jeong-Min Park, Nadima Uprety, Rejeena Shrestha, Francia Reyes Silva, Merve Dede, John Watts, Sunil Acharya, Donghai Xiong et al. · 2025 · Cancer Cell
23. Massively parallel knock-in engineering of human T cells
    Xiaoyun Dai, Jonathan Joon-Young Park, Yaying Du, Zhenkun Na, Stanley Z. Lam, Ryan Dz-Wei Chow, Paul A. Renauer, Jianlei Gu, Xin Shan, Zhiyuan Chu et al. · 2023 · Nature Biotechnology
24. Cell Reprogramming With CRISPR/Cas9 Based Transcriptional Regulation Systems
    К. М. Шакирова, Viktoriia Y. Ovchinnikova, Erdem Bairovich Dashinimaev · 2020 · Frontiers in Bioengineering and Biotechnology
25. Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence
    Xingwu Zhou, Moyuan Qu, Peyton J. Tebon, Xing Jiang, Canran Wang, Yumeng Xue, Jixiang Zhu, Shiming Zhang, Rahmi Öklü, Shiladitya Sengupta et al. · 2020 · Advanced Science
26. Efficient viral delivery of Cas9 into human safe harbor
    Hideki Hayashi, Yoshinao Kubo, Mai Izumida, T. Matsuyama · 2020 · Scientific Reports
27. A genome-wide in vivo CRISPR screen identifies essential regulators of T cell migration to the CNS in a multiple sclerosis model
    Arek Kendirli, Clara de la Rosa del Val, Katrin F. Lämmle, Klara Eglseer, Isabel Bauer, Vladyslav Kavaka, Stephan Winklmeier, La Zhuo, Christian Werner Wichmann, Lisa Ann Gerdes et al. · 2023 · Nature Neuroscience
28. In vivo site-specific engineering to reprogram T cells
    William A. Nyberg, Pierre-Louis Bernard, Wayne Ngo, Charlotte H. Wang, Jonathan Ark, Allison Rothrock, Gina M. Borgo, Gabriella R. Kimmerly, Jae Hyung Jung, Vincent Allain et al. · 2026 · Nature
29. Ubiquitin Ligases in Cancer Immunotherapy – Balancing Antitumor and Autoimmunity
    Yu Fujita, Roberto Tinoco, Yan Li, Daniela Senft, Ze’ev A. Ronai · 2019 · Trends in Molecular Medicine
30. Optimized CRISPR-mediated gene knockin reveals FOXP3-independent maintenance of human Treg identity
    Lam, Avery J., Lin, David T.S., Gillies, Jana K., Uday, Prakruti, Pesenacker, Anne M., Kobor, Michael S., Levings, Megan K. · 2021 · Cell Reports
31. UBASH3A Regulates the Synthesis and Dynamics of TCR–CD3 Complexes
    Yan Ge, Taylor K. Paisie, Sixue Chen, PATRICK J. CONCANNON · 2019 · The Journal of Immunology
32. All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy
    Evripidis Lanitis, George Coukos, Melita B. Irving · 2020 · Current Opinion in Biotechnology
33. Advances in Genomics for Drug Development
    Roberto Spreafico, Leah B. Soriaga, Johannes Grosse, Herbert W. Virgin, Amalio Telenti · 2020 · Genes
34. In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma
    Nelson H. Knudsen, Giulia Escobar, Felix Korell, Tamina Kienka, Celeste Nobrega, Seth Anderson, Andrew Y. Cheng, Maria Zschummel, Alexander Armstrong, Amanda A. Bouffard et al. · 2025 · Nature
35. A CRISPR–Cas9 system for multiple genome editing and pathway assembly in Candida tropicalis
    Lihua Zhang, Haibing Zhang, Yufei Liu, Jingyu Zhou, Wei Shen, Li Liu, Qi Li, Xianzhong Chen · 2019 · Biotechnology and Bioengineering
36. ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors
    Yeonsun Hong, Brandon Lee Walling, Hye-Ran Kim, William S. Serratelli, John R. Lozada, Cooper J. Sailer, Andrea M. Amitrano, Kihong Lim, Raj Kumar Mongre, Kyun‐Do Kim et al. · 2023 · Nature Immunology
37. Genome-wide CRISPR screen in human T cells reveals regulators of FOXP3
    Kelvin Y. Chen, Tatsuya Kibayashi, Ambre Giguelay, Mayu Hata, Shunsuke Nakajima, Norihisa Mikami, Yusuke Takeshima, Kenji Ichiyama, Ryusuke Omiya, Leif S. Ludwig et al. · 2025 · Nature
38. Efficient generation of isogenic primary human myeloid cells using CRISPR-Cas9 ribonucleoproteins
    Joseph B Hiatt, Devin August Cavero, Michael McGregor, Weihao Zheng, Jonathan M. Budzik, Theodore L. Roth, Kelsey M. Haas, David Wu, Ujjwal Rathore, Anke Meyer‐Franke et al. · 2021 · Cell Reports
39. IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors
    Yan Zou, Bo Liu, Long Li, Qinan Yin, Jiaxing Tang, Zhengyu Jing, Xingxu Huang, Xuekai Zhu, Tian H. Chi · 2021 · Cancer Letters
40. Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity
    Darienne R. Myers, Clare L. Abram, David P. Wildes, Amira Belwafa, Alia M. N. Welsh, Christopher J. Schulze, Tiffany J. Choy, Tram Nguyen, Neil Omaque, Yongmei Hu et al. · 2020 · Frontiers in Immunology
41. Genome-wide CRISPR/Cas9-knockout in human induced Pluripotent Stem Cell (iPSC)-derived macrophages
    Elena Navarro‐Guerrero, Chwen Tay, Justin P. Whalley, Sally A. Cowley, Benjamin Davies, Julian Charles Knight, Daniel V. Ebner · 2021 · Scientific Reports
42. New approaches to moderate CRISPR-Cas9 activity: Addressing issues of cellular uptake and endosomal escape
    Maja van Hees, Sofie Slott, Anders Højgaard Hansen, Heon Seok Kim, Hanlee P. Ji, Kira Astakhova · 2021 · Molecular Therapy
43. Method of moments framework for differential expression analysis of single-cell RNA sequencing data
    Min Cheol Kim, Rachel E. Gate, David S. Lee, Andrew Tolopko, Andrew C. Lu, Erin D. Gordon, Eric Shifrut, Pablo E. García-Nieto, Alexander Marson, Vasilis Ntranos et al. · 2024 · Cell
44. Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin
    Jessica Wagner, Elizabeth Wickman, Timothy I. Shaw, Alejandro Allo Anido, Deanna M. Langfitt, Jinghui Zhang, Shaina N. Porter, Shondra M. Pruett‐Miller, Heather S. Tillman, Giedre Krenciute et al. · 2020 · Cancer Immunology Research
45. A Perspective on Synthetic Biology in Drug Discovery and Development—Current Impact and Future Opportunities
    Florian David, Andrew M. Davis, Michael Gossing, Martin A. Hayes, Elvira Romero, Louis H. Scott, Mark J Wigglesworth · 2021 · SLAS DISCOVERY
46. In vivo CRISPR screens reveal a HIF-1α-mTOR-network regulates T follicular helper versus Th1 cells
    Bonnie Huang, James D. Phelan, Silvia Preite, Julio Gómez‐Rodríguez, Kristoffer Haurum Johansen, Hirofumi Shibata, Arthur L. Shaffer, Qin Xu, Brendan M. Jeffrey, Martha Kirby et al. · 2022 · Nature Communications
47. CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
    Ezgi Elmas, Noushin Saljoughian, Marcelo de Souza Fernandes Pereira, Brian P. Tullius, Kinnari Sorathia, Robin J. Nakkula, Dean Anthony Lee, Meisam Naeimi Kararoudi · 2022 · Frontiers in Oncology
48. Current Status of CRISPR/Cas9 Application in Clinical Cancer Research: Opportunities and Challenges
    Saeed Rafii, Emad M. Tashkandi, Nedal Bukhari, Humaid Obaid Al-Shamsi · 2022 · Cancers
49. Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens
    Michael R. Schlabach, Sharon Lin, Zachary R. Collester, Christopher Wrocklage, Sol Shenker, Conor Calnan, Tianlei Xu, Hugh Gannon, Leila J. Williams, Frank Thompson et al. · 2023 · Journal of Clinical Investigation
50. CRISPR screen in mechanism and target discovery for cancer immunotherapy
    Dan Liu, Xuan Zhao, Anqun Tang, Xiyue Xu, Shuci Liu, Li Zha, Wen Ma, Junnian Zheng, Ming Shi · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
51. Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy
    Lukman Olalekan Afolabi, Mariam Olanrewaju Afolabi, Musbahu Muhammad Sani, Wahab Oluwanisola Okunowo, Dehong Yan, Liang Chen, Yaou Zhang, Xiaochun Wan · 2021 · Clinical & Translational Immunology
52. Exploiting Single-Cell Tools in Gene and Cell Therapy
    Daniel Bode, Alyssa H. Cull, Juan A. Rubio-Lara, David G. Kent · 2021 · Frontiers in Immunology
53. Ultrasound Control of Genomic Regulatory Toolboxes for Cancer Immunotherapy
    Yiqian Wu, Ziliang Huang, Yahan Liu, Peixiang He, Yuxuan Wang, Liyanran Yan, Xinhui Wang, Shanzi Gao, Xintao Zhou, Chi Woo Yoon et al. · 2024 · Nature Communications
54. Massively Parallel CRISPR‐Based Genetic Perturbation Screening at Single‐Cell Resolution
    Junyun Cheng, Gaole Lin, Tianhao Wang, Yunzhu Wang, Wenbo Guo, Jie Liao, Penghui Yang, Jie Chen, Xin Shao, Xiaoyan Lu et al. · 2022 · Advanced Science
55. Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
    Vladimir Laletin, Pierre-Louis Bernard, Cathy Costa Da Silva, Geoffrey C. Guittard, Jacques A. Nunès · 2023 · Journal for ImmunoTherapy of Cancer
56. Current status and perspectives of regulatory T cell-based therapy
    Guojun Qu, Jieqiong Chen, Yangyang Li, Yaqin Yuan, Rui Liang, Bin Li · 2022 · Journal of genetics and genomics/Journal of Genetics and Genomics
57. Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screens
    Zachary H. Walsh, Parin Shah, Neeharika Kothapalli, Shivem B. Shah, Gergő Nikolényi, D. Zack Brodtman, Giuseppe Leuzzi, Meri Rogava, Michael Mu, Patricia Ho et al. · 2024 · Nature Biotechnology
58. Differential Gene Set Enrichment Analysis: a statistical approach to quantify the relative enrichment of two gene sets
    James H. Joly, William E. Lowry, Nicholas Alexander Graham · 2020 · Bioinformatics
59. Challenges and opportunities in cell expansion for cultivated meat
    Michelle Hauser, Amit Zirman, Roni Rak, Iftach Nachman · 2024 · Frontiers in Nutrition
60. Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells
    Ce Luo, Rui Zhang, Rui Guo, Lijian Wu, Teng Xue, Yufeng He, Yiteng Jin, Yanping Zhao, Zongxu Zhang, Peng Zhang et al. · 2025 · Immunity
61. The Uproar Over Gene-Edited Babies: A Semantic Network Analysis of CRISPR on Twitter
    Christopher Calabrese, Jieyu Ding, Benjamin J. Millam, George A. Barnett · 2019 · Environmental Communication
62. SOCS: negative regulators of cytokine signaling for immune tolerance
    Akihiko Yoshimura, Minako Ito, Setsuko Mise‐Omata, Makoto Ando · 2021 · International Immunology
63. Decoding heterogeneous single-cell perturbation responses
    Bicna Song, Dingyu Liu, Weiwei Dai, Natalie F. McMyn, Qingyang Wang, Dapeng Yang, Adam Krejčí, Anatoly Vasilyev, Nicole Untermoser, Anke Loregger et al. · 2025 · Nature Cell Biology
64. Genome-scale perturb-seq in primary human CD4+ T cells maps context-specific regulators of T cell programs and human immune traits
    Ronghui Zhu, Emma Dann, Jun Yan, Justine Reyes Retana, Ryunosuke Goto, Reese C Guitche, Lillian Brixi, Mineto Ota, Austin Hartman, Theodore L. Roth et al. · 2026 · Cell
65. CRISPR-Cas9 Ribonucleoprotein-Mediated Genomic Editing in Mature Primary Innate Immune Cells
    Luke Riggan, Andrew D. Hildreth, Marion Rolot, Yung Yu Wong, William Satyadi, Ryan Sun, Christopher Huerta, Timothy Edward O’Sullivan · 2020 · Cell Reports
66. PPP2R2B downregulation is associated with immune evasion and predicts poor clinical outcomes in triple-negative breast cancer
    Zheng Li, Yaming Li, Xiaolong Wang, Qifeng Yang · 2021 · Cancer Cell International
67. The new progress in cancer immunotherapy
    Ajmeri Sultana Shimu, Hua-xing Wei, Qiangsheng Li, Xucai Zheng, Bofeng Li · 2022 · Clinical and Experimental Medicine
68. A new Bayesian factor analysis method improves detection of genes and biological processes affected by perturbations in single-cell CRISPR screening
    Zhou, Yifan, Luo, Kaixuan, Liang, Lifan, Chen, Mengjie, He, Xin · 2023 · Nature Methods
69. Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challenges
    Dennis Christoph Harrer, Sin‐Syue Li, Marcell Kaljanac, Markus Barden, Hong Pan, Hinrich Abken · 2023 · Frontiers in Immunology
70. Engineering CAR T cells for enhanced efficacy and safety
    Yiqian Wu, Ziliang Huang, Reed E. S. Harrison, Longwei Liu, Linshan Zhu, Yinglin Situ, Yingxiao Wang · 2022 · APL Bioengineering
71. A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor
    Huadong Chen, Morgan E. Diolaiti, Patrick C. O’Leary, Ajda Rojc, Nevan J. Krogan, Minkyu Kim, Alan Ashworth · 2022 · Molecular Cancer Therapeutics
72. Mind the GAP: RASA2 and RASA3 GTPase-activating proteins as gatekeepers of T cell activation and adhesion
    Kristoffer Haurum Johansen, Dominic P. Golec, Klaus Okkenhaug, Pamela L. Schwartzberg · 2023 · Trends in Immunology
73. IFNγ mediates the resistance of tumor cells to distinct NK cell subsets
    Tomáš Hofman, Siu Wang Ng, Irene Garcés-Lázaro, Florian Heigwer, Michael Boutros, Adelheid Cerwenka · 2024 · Journal for ImmunoTherapy of Cancer
74. One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency
    Julia Körholz, Anastasia Gabrielyan, John M. Sowerby, Felix Boschann, Lan‐Sun Chen, Diana Paul, David Brandt, Janina Kleymann, Martin Kolditz, Nicole Toepfner et al. · 2021 · Frontiers in Immunology
75. Integrated epigenetic and genetic programming of primary human T cells
    Laine Goudy, Alvin S. Ha, Ashir A. Borah, Jennifer M. Umhoefer, Lauren Chow, Carinna Tran, Aidan Winters, Alexis Talbot, Rosmely Hernandez, Zhongmei Li et al. · 2025 · Nature Biotechnology
76. CRISPR screen in cancer: status quo and future perspectives.
    Chenglong He, Siqi Han, Yue Chang, Meijuan Wu, Yulu Zhao, Cheng Yeh Chen, Xiaoyuan Chu · 2021 · PubMed Central
77. Cell Cycle Entry Control in Naïve and Memory CD8+ T Cells
    David A. Lewis, Tony Ly · 2021 · Frontiers in Cell and Developmental Biology
78. In vivo CRISPR screens identify a dual function of MEN1 in regulating tumor–microenvironment interactions
    Peiran Su, Yin Liu, Tianyi Chen, Yibo Xue, Yong Zeng, Guanghui Zhu, Sujun Chen, Mona Teng, Xinpei Ci, Mengdi Guo et al. · 2024 · Nature Genetics
79. Germline mutations in a G protein identify signaling cross-talk in T cells
    Hyoungjun Ham, Huie Jing, Ian T. Lamborn, Megan M. Kober, Alexey Koval, Yamina A. Berchiche, David Eric Anderson, Kirk M. Druey, Judith N. Mandl, Bertrand Isidor et al. · 2024 · Science
80. CRISPR-based functional genomics in human dendritic cells
    Marco Jost, Amy N. Jacobson, Jeffrey A. Hussmann, Giana Cirolia, Michael Andrew Fischbach, Jonathan S. Weissman · 2021 · eLife
81. Tumor immunology CRISPR screening: present, past, and future
    Matthew B. Dong, Kaiyuan Tang, Xiaoyu Zhou, Jingjia J. Zhou, Sidi Chen · 2021 · Trends in cancer
82. A single-amino acid substitution in the adaptor LAT accelerates TCR proofreading kinetics and alters T-cell selection, maintenance and function
    Wan‐Lin Lo, Miriam Kuhlmann, Gabrielle A. Rizzuto, H. Atakan Ekiz, Elizabeth Motunrayo Kolawole, Monica Patricia Revelo, Rakieb Andargachew, Zhongmei Li, Yuan-Li Tsai, Alexander Marson et al. · 2023 · Nature Immunology
83. Next-generation forward genetic screens: uniting high-throughput perturbations with single-cell analysis
    John A. Morris, Jennifer S. Sun, Neville E. Sanjana · 2023 · Trends in Genetics
84. VAV1 as a putative therapeutic target in autoimmune and chronic inflammatory diseases
    Markus Friedrich Neurath, Leslie J. Berg · 2024 · Trends in Immunology
85. Adapting systems biology to address the complexity of human disease in the single-cell era
    David S. Fischer, Martin Arreola Villanueva, Peter S. Winter, Alex K. Shalek · 2025 · Nature Reviews Genetics
86. Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2
    Patrick C. O’Leary, Huadong Chen, Yagmur Umay Doruk, Tess Williamson, Benjamin J. Polacco, Andrew S. McNeal, Tanushree Shenoy, Nupura Kale, Julia C. Carnevale, Erica J. Stevenson et al. · 2022 · Cancer Research
87. Post-translational modification-centric base editor screens to assess phosphorylation site functionality in high throughput
    Patrick H. Kennedy, Amin Alborzian Deh Sheikh, Matthew Balakar, Alexander Curtis Jones, Meagan E. Olive, Mudra Hegde, Maria I. Matias, Natan Pirete, Rajan A. Burt, Jonathan Ma Levy et al. · 2024 · Nature Methods
88. Chimeric antigen receptor T cells applied to solid tumors
    Zhongguo Zhou, Can Tao, Jianting Li, Johnny Cheuk On Tang, Albert S. C. Chan, Yuanyuan Zhou · 2022 · Frontiers in Immunology
89. Pooled genetic screens with image‐based profiling
    Russell T. Walton, Avtar K Singh, Paul C. Blainey · 2022 · Molecular Systems Biology
90. DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell–mediated antitumor immunity
    Michael J. Wichroski, Joseph L. Benci, Si-Qi Liu, Louis S. Chupak, Jie Fang, Carolyn Cao, Cindy Wang, Joelle M. Onorato, Hongchen Qiu, Yongli Shan et al. · 2023 · Science Translational Medicine
91. Using CRISPR to enhance T cell effector function for therapeutic applications
    Julian J. Freen‐van Heeren · 2020 · Cytokine X
92. Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies
    Minghua Xiang, Huayi Li, Yuanyuan Zhan, Ding Ma, Qinglei Gao, Yong Fang · 2024 · Molecular Cancer
93. Integrating multiplexed imaging and multiscale modeling identifies tumor phenotype conversion as a critical component of therapeutic T cell efficacy
    John W. Hickey, Eran Agmon, Nina B. Horowitz, Tze-Kai Tan, Matthew Lamore, John B. Sunwoo, Markus W. Covert, Garry P. Nolan · 2024 · Cell Systems
94. mRNA-based therapeutic strategies for cancer treatment
    Thilelli Taibi, Sehyun Cheon, Fabiana Perna, Ly Vu · 2024 · Molecular Therapy
95. Dissecting the Tumor–Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach
    Gregory M. Chen, Andrew Azzam, Yangyang Ding, David Maxwell Barrett, Stephan A. Grupp, Kai Tan · 2020 · Clinical Cancer Research
96. Strategies for developing PD-1 inhibitors and future directions
    Wensheng Chen, Yuan Huang, Wenting Pan, Meng Xu, Liang Chen · 2022 · Biochemical Pharmacology
97. Coengineering specificity, safety, and function into T cells for cancer immunotherapy
    Greta Maria Paola Giordano Attianese, Sarah Ash, Melita B. Irving · 2023 · Immunological Reviews
98. A large-scale benchmark for network inference from single-cell perturbation data
    Chevalley, Mathieu, Roohani, Yusuf H., Mehrjou, Arash, Leskovec, Jure, Schwab, Patrick · 2025 · Communications Biology
99. Combined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells
    David Yudovich, Alexandra Bäckström, Ludwig Schmiderer, Kristijonas Žemaitis, Agatheeswaran Subramaniam, Jonas Larsson · 2020 · Scientific Reports
100. Update on Autophagy Inhibitors in Cancer: Opening up to a Therapeutic Combination with Immune Checkpoint Inhibitors
     Eloïne Bestion, Éric Raymond, Soraya Mezouar, Philippe Halfon · 2023 · Cells